1 |
Barbas, III C. F., Bain, J. D., Hoekstra, D. M., and Lerner, R. A. (1992) Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc. Natl. Acad. Sci. USA 89, 4457–4461
|
2 |
Bera, T. K., Onda, M., Brinkmann, U., and Pastan, I. (1998) A bivalent disulfide-stabilized fv with improved antigen binding to erbb2. J. Mol. Biol. 281, 475–483
DOI
ScienceOn
|
3 |
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., et al. (1988) Single-chain antigen-binding proteins. Science 242, 423–426
DOI
|
4 |
Colcher, D., Pavlinkova, G., Beresford, G., Booth, B. J., Choudhury, A., et al. (1998) Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q. J. Nucl. Med. 42, 225–241
|
5 |
Daeron, M. (1997) Fc receptor biology. Ann. Rev. Immunol. 15, 203–234
DOI
ScienceOn
|
6 |
Dall'Acqua, W. F., Woods, R. M., Ward, E. S., Palaszynski, S. R., Patel, N. K., et al. (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: Biological consequences. J. Immunol. 169, 5171–5180
|
7 |
Fuchs, P., Breitling, F., Dubel, S., Seehaus, T., and Little, M. (1991) Targeting recombinant antibodies to the surface of Escherichia coli: fusion to a peptidoglycan associated lipoprotein. Bio-Technology 9, 1369–1372
ScienceOn
|
8 |
Griffiths, A. D., Williams, S. C., Hartley, O., Tomlinson, I. M., Waterhouse, P., et al. (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13, 3245–3260
|
9 |
Hawkins, R. E., Russell, S. J., and Winter, G. (1992) Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol. 226, 889-896
DOI
|
10 |
Hoogenboom, H. R. and Winter, G. (1992) Bypassing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J. Mol. Biol. 227, 381–388
DOI
|
11 |
Hoogenboom, H. R., de Bruine, A. P., Hufton, S. E., Hoet, R. M., Arends, J. W., et al. (1998) Antibody phage display technology and its applications. Immunotechnology 4, 1–20
DOI
ScienceOn
|
12 |
King, D. J., Turner, A., Farnsworth, A. P., Adair, J. R., Owens, R. J., et al. (1994) Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 54, 6176–6185
|
13 |
Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J., and Pastan, I. (2002) Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin. Cancer Res. 8, 995–1002
|
14 |
Kuan, C. T., Wikstrand, C. J., Archer, G., Beers, R., Pastan, I., et al. (2000) Increased binding affinity enhances targeting of glioma xenografts by EGFRVIII-specific scFV. Int. J. Cancer 88, 962–969
DOI
ScienceOn
|
15 |
Neuberger, M. S., Ehrenstein, M. R., Klix, N., Jolly, C. J., Yelamos, J., et al. (1998) Monitoring and interpreting the intrinsic features of somatic hypermutation. Immunol. Rev. 162, 107–116
DOI
ScienceOn
|
16 |
Nissim, A., Hoogenboom, H. R., Tomlinson, I. M., Flynn, G., Midgley, C., et al. (1994) Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J. 13, 692–698
|
17 |
Schier, R., Bye, J., Apell, G., McCall, A., Adams, G. P., et al. (1996a) Isolation of high-affinity monomeric human anti-cerbB- 2 single chain Fv using affinity-driven selection. J. Mol. Biol. 255, 28–43
DOI
ScienceOn
|
18 |
Stavenhagen, J. and Vijh, S., Int. Pub. No. WO 2004/063351 A2
|
19 |
Tsurushita, N., Hinton, P. R., and Kumar, S. (2005) Design of humanized antibodies: from anti-Tac to Zenapax. Methods 36, 69-83
DOI
ScienceOn
|
20 |
de Wildt, R. M., Finnern, R., Ouwehand, W. H., Griffiths, A. D., van Venrooij, W. J., et al. (1996) Characterization of human variable domain antibody fragments against the U1 RNAassociated A protein, selected from a synthetic and patientderived combinatorial V gene library. Eur. J. Immunol. 26, 629–639
|
21 |
Wu, A. M. (2004) Engineering multivalent antibody fragments for in vivo targeting. Methods Mol. Biol. 248, 209–225
|
22 |
Yang, W. P., Green, K., Pinz-Sweeney, S., Briones, A. T., Burton, D. R., et al. (1995) CDR Walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol. Biol. 254, 392–403
DOI
ScienceOn
|
23 |
Treon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., et al. (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J. Immunother. 24, 263–271
DOI
|
24 |
Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S., and Foeller, C. (1991) Sequences of Proteins of Immunological Interests, 5th ed., United States Public Health Service, National Institutes of Health, Bethesda
|
25 |
Francisco, J. A., Campbell, R., Iverson, B. L., and Georgiou, G. (1993) Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface. Proc. Natl. Acad. Sci. USA 90, 10444–10448
|
26 |
Georgiou, G., Stathopoulos, C., Daugherty, P. S., Nayak, A. R., Iverson, B. L., et al. (1997) Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Nat. Biotechnol. 15, 29–34
ScienceOn
|
27 |
Griffiths, A. D. and Duncan, A. R. (1998) Strategies for selection of antibodies by phage display. Curr. Opin. Biotechnol. 9, 102–108
DOI
ScienceOn
|
28 |
Holliger, P., Prospero, T., and Winter, G. (1993) 'Diabodies': Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90, 6444–6448
|
29 |
Gunneriusson, E., Samuelson, P., Uhlen, M., Nygren, P. A., and Stahl, S. (1996) Surface display of a functional single-chain Fv antibody on staphylococci. J. Bacteriol. 178, 1341–1346
|
30 |
Bell, M. and Kamm, M. (2000) The clinical role of anti-TNFa antibody treatment in Crohn's disease. Aliment. Phamacol. Ther. 14, 501-514
DOI
ScienceOn
|
31 |
Mendez, M., Green, L., Corvalan, J., Jia, X. C., Maynard-Currie, C., et al. (1997) Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15, 146–156
DOI
ScienceOn
|
32 |
Wright, A. and Morrison, S. L. (1998) Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J. Immunol. 160, 3393– 3402
|
33 |
Gelderman, K. A., Tomlinson, K. S., Ross, G. D., and Gorter, A. (2004) Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25, 158–164
DOI
ScienceOn
|
34 |
Hanes, J., Jermutus, L., Weber-Bornhauser, S., Bosshard, H. R., and Pluckthun, A. (1998) Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc. Natl. Acad. Sci. USA 95, 14130–14135
|
35 |
Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., et al. (2003) Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279, 6213–6216
DOI
ScienceOn
|
36 |
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., et al. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcΓRIII and antibodydependent cellular toxicity. J. Biol. Chem. 277, 26733–26740
DOI
ScienceOn
|
37 |
Fishwild, D. M., O'Donnell, S. L., Bengoechea, T., Hudson, D. V., Harding, F., et al. (1996) High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14, 845–851
DOI
ScienceOn
|
38 |
Lund, J., Takahashi, N., Pound, J. D., Goodall, M., and Jefferis, R. (1996) Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fcγ receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol. 157, 4963–4969
|
39 |
Medzihradszky, K. F., Spencer, D. I., Sharma, S. K., Bhatia, J., Pedley, R. B., et al. (2004) Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. Glycobiology 14, 27–37
DOI
ScienceOn
|
40 |
Dall'Acqua, W. F., Damschroder, M. M., Zhang, J., Woods, R. M., Widjaja, L., et al. (2005) Antibody humanization by framework shuffling. Methods. 36, 43-60
DOI
ScienceOn
|
41 |
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., and Winter, G. (1996) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522-525
DOI
ScienceOn
|
42 |
Maynard, J. A., Maassen, C. B., Leppla, S. H., Brasky, K., Patterson, J. L., et al. (2002) Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20, 597–601
DOI
ScienceOn
|
43 |
Woodle, M. C. and Lasic, D. D. (1992) Sterically stabilized liposomes. Biochim. Biophys. Acta 1113, 171–199
ScienceOn
|
44 |
Duenas, M. and Borrebaeck, C. A. (1994) Clonal selection and amplification of phage displayed antibodies by linking antigen recognition and phage replication. Bio-Technology 12, 999–1002
ScienceOn
|
45 |
Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., et al. (1998) Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58, 485–490
|
46 |
Mattheakis, L. C., Bhatt, R. R., and Dower, W. J. (1994) An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc. Natl. Acad. Sci. USA 91, 9022–9026
|
47 |
Tao, M. H., Canfield, S. M., and Morrison, S. L. (1991) The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J. Exp. Med. 173, 1025–1028
DOI
ScienceOn
|
48 |
Neal, Z. C., Yang, J. C., Rakhmilevich, A. L., Buhtoiarov, I. N., Lum, H. E., et al. (2004) Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin. Cancer Res. 10, 4839–4847
DOI
ScienceOn
|
49 |
Tsutsumi, Y., Onda, M., Nagata, S., Lee, B., Kreitman, R. J., et al. (2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA 97, 8548–8553
|
50 |
Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., Davis, C. G., et al. (1999b) Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236–1243
|
51 |
Chang, C. H., Sharkey, R. M., Rossi, E. A., Karacay, H., McBride, W., et al. (2002) Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol. Cancer Ther. 1, 553–563
|
52 |
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., et al. (2001) Engineered antibodies with increased activity to recruit complement. J. Immunol. 166, 2571–2575
|
53 |
Hassan, R., Lerner, M. R., Benbrook, D., Lightfoot, S. A., Brackett, D. J., et al. (2002) Antitumor activity of SS (dsFv) PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin. Cancer Res. 8, 3520–3526
|
54 |
Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V. J., et al. (1995a) Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol. 13, 2281–2292
|
55 |
Ward, E. S., Gussow, D., Griffiths, A. D., Jones, P. T., and Winter, G. (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341, 544–546
DOI
ScienceOn
|
56 |
Brinkmann, U., Reiter, Y., Jung, S. H., Lee, B., and Pastan, I. (1993) A recombinant immunotoxin containing a disulfidestabilized Fv fragment Proc. Natl. Acad. Sci. USA 90, 7538– 7542
|
57 |
Hwang, W. Y. K. and Foote, J. (2005) Immunogenicity of engineered antibodies. Methods 36, 3-10
DOI
ScienceOn
|
58 |
Wu, H., Beuerlein, G., Nie, Y., Smith, H., Lee, B. A., et al. (1998) Stepwise in vitro affinity maturation of Vitaxin, an (v)3-specific humanized mAb. Proc. Natl. Acad. Sci. USA 95, 6037–6042
|
59 |
Barbas, III C. F., Hu, D., Dunlop, N., Sawyer, L., Cababa, D., et al. (1994) In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc. Natl. Acad. Sci. USA 91, 3809–3813
|
60 |
Boder, E. T. and Wittrup, K. D. (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553–557
DOI
ScienceOn
|
61 |
Kuby, J. (1997) Immunology. New York: Freeman. p. 664
|
62 |
Hanes, J. and Pluckthun, A. (1999) In vitro selection methods for screening of peptide and protein libraries. Curr. Top. Microbiol. Immunol. 243, 107–122
|
63 |
Schier, R., McCall, A., Adams, G. P., Marshall, K. W., Merritt, H., et al. (1996b) Isolation of picomolar affinity anti-c-erbB- 2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263, 551–567
DOI
ScienceOn
|
64 |
Spada, S., Krebber, C., and Pluckthun, A. (1997) Selectively infective phages (SIP). Biol. Chem. 378, 445–456
ScienceOn
|
65 |
Huls, G. A., Heijnen, I. A., Cuomo, M. E., Koningsberger, J. C., Wiegman, L., et al. (1999) A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat. Biotechnol. 17, 276–281
DOI
ScienceOn
|
66 |
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., et al. (2000) Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164, 4178–4184
|
67 |
Chowdhury, P. S. (2003) Engineering hot spots for affinity enhancement of antibodies. Methods Mol. Biol. 2007, 179–196
|
68 |
Chowdhury, P. S. and Pastan, I. (1999) Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. 17, 568–572
DOI
ScienceOn
|
69 |
Hwang, W. Y. K., Almagro, J. C., Buss, T. N., Tan, P., and Foote, J. (2005) Use of human germline genes in a CDR homologybased approach to antibody humanization. Methods 36, 35-42
DOI
ScienceOn
|
70 |
Chapman, A. P. (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54, 531–545
DOI
ScienceOn
|
71 |
Kashmiri, S. V., De Pascalis, R., Gonzales, N. R., and Schlom, J. (2005) SDR grafting--a new approach to antibody humanization. Methods. 36, 25-34
DOI
ScienceOn
|
72 |
Lazar, G., Chirino, A. J., Dang, W., Desjarlais, J. R., Doberstein, S. K., et al. Int. Pub. No. WO 2004/029207 A2
|
73 |
Roberts, R. and Szostak, J. W. (1997) RNApeptide fusions for the in vitro selection of peptides and proteins. Proc. Natl. Acad. Sci. USA 94, 12297–12302
|
74 |
Smallshaw, J. E., Ghetie, V., Rizo, J., Fulmer, J. R., Trahan, L. L., et al. (2003) Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat. Biotechnol. 21, 387–389
DOI
ScienceOn
|
75 |
Wu, H., Nie, Y., Huse, W. D., and Watkins, J. D. (1999) Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J. Mol. Biol. 294, 151–162
DOI
ScienceOn
|
76 |
Bruggemann, M. and Taussig, M. J. (1997) Production of human antibody repertoires in transgenic mice. Curr. Opin. Biotechnol. 8, 455–458
DOI
ScienceOn
|
77 |
Glaser, S. M., Yelton, D. E., and Huse, W. D. (1992) Antibody engineering by codon-based mutagenesis in a filamentous phage vector system. J. Immunol. 149, 3903–3913
|
78 |
de Kruif, J., Boel, E., and Logtenberg, T. (1995) Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J. Mol. Biol. 248, 97–105
DOI
ScienceOn
|
79 |
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., et al. (2001) High resolution mapping of the binding site on human IgG1 for , and FcRn and design of IgG1 variants with improved binding to the R. J. Biol. Chem. 276, 6591–6604
DOI
ScienceOn
|
80 |
He, M. and Taussig, M. J. (1997) Antibodyribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res. 25, 5132–5134
DOI
|
81 |
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., et al. (1996) Human antibodies with subnanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 14, 309–314
DOI
ScienceOn
|
82 |
Hu, S., Shively, L., Raubitschek, A., Sherman, M., Williams, L. E., et al. (1996) Minibody: A novel engineered anticarcinoembryonic antigen antibody fragment (single-chain Fv-C(H)3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56, 3055–3061
|
83 |
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., and Oi, V. T. (1984) Chimeric human antibody molecules; mouse antigenbinding domains with human constant region domains. Proc. Natl Acad. Sci. USA 21, 6851-6855
|
84 |
Sensel, M. G., Kane, L. M., and Morrison, S. L. (1977) Amino acid differences in the N-terminus of CH2 influence the relative abilities of IgG2 and IgG3 to active complement. Mol. Immunol. 34, 1019–1029
|
85 |
Wabl, M., Cascalho, M., and Steinberg, C. (1999) Hypermutation in antibody affinity maturation. Curr. Opin. Immunol. 11, 186–189
DOI
ScienceOn
|
86 |
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., et al. (1991) Bypassing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581–597
DOI
|
87 |
Zhang, M. Y., Shu, Y., Rudolph, D., Prabakaran, P., Labrijn, A. F., et al. (2004) Improved breadth and potency of an HIV-1- neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J. Mol. Biol. 335, 209– 219
DOI
ScienceOn
|
88 |
Tao, M. H., Smith, R. I., and Morrison, S. L. (1993) Structural features of human immunoglobulin G that determine isotypespecific differences in complement activation. J. Exp. Med. 178, 661–667
DOI
ScienceOn
|
89 |
Yang, X. D., Corvalan, J. R., Wang, P., Roy, C. M., and Davis, C. G. (1999a) Fully human antiinterleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J. Leukocyte Biol. 66, 401–410
|
90 |
Chapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S., et al. (1999) Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 17, 780–783
DOI
ScienceOn
|
91 |
Wu, A. M. and Yazaki, P. J. (2000) Designer genes: recombinant antibody fragments for biological imaging. Q. J. Nucl. Med. 44, 268–283
|
92 |
Santimaria, M., Moscatelli, G., Viale, G. L., Giovannoni, L., Neri, G., et al. (2003) Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 9, 571–579
|
93 |
Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G. M., et al. (2000) Biologic response of B lymphoma cells to anti- CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood 95, 3900–3908
|
94 |
Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V. J., et al. (1995b) Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. J. Hematother. 4, 471– 475
ScienceOn
|
95 |
Klein, M., Haeffner-Cavaillon, N., Isenman, D. E., Rivat, C., Navia, M. A., et al. (1981) Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region. Proc. Natl. Acad. Sci. USA 78, 524–528
|
96 |
Chames, P., Willemsen, R. A., Rojas, G., Dieckmann, D., Rem, L., et al. (2002) TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J. Immunol. 169, 1110–1118
|
97 |
Hanes, J., Schaffitzel, C., Knappik, A., and Plückthun, A. (2000) Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 18, 1287-1292
DOI
ScienceOn
|
98 |
Ho, M., Kreitman, R. J., Onda, M., and Pastan, I. (2005) In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J. Biol. Chem. 280, 607–617
|
99 |
Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., et al. (2000) Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs with randomized trinucleotides. J. Mol. Biol. 296, 57– 86
DOI
ScienceOn
|
100 |
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., et al. (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278, 3466–3473
DOI
ScienceOn
|